Crossmark

Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer

Crossref DOI link: https://doi.org/10.1038/ncb3341

Published Online: 2016-04-18

Published Print: 2016-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lien, Evan C.

Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Juvekar, Ashish

Hu, Hai

Asara, John M.

Cantley, Lewis C.

Toker, Alex
License Information

Text and Data Mining valid from 2016-04-18
More Information

Article History

Received: 23 September 2015

Accepted: 11 March 2016

First Online: 18 April 2016

Competing interests

: L.C.C. owns equity in, receives compensation from, and serves on the Board of Directors and Scientific Advisory Board of Agios Pharmaceuticals. Agios Pharmaceuticals is identifying metabolic pathways of cancer cells and developing drugs to inhibit such enzymes to disrupt tumour cell growth and survival.